CLINICAL TRIALS PROFILE FOR ERYTHROMYCIN STEARATE

All Clinical Trials for erythromycin stearate

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT02528981 ↗	Effect of Probiotics on GBS Colonization Status During Pregnancy: A Pilot Randomized Controlled Trial	Completed	Chr Hansen	N/A	2015-08-01	Group B Streptococcus (GBS) is the leading cause of neonatal morbidity and mortality in Canada. It may be passed from a study participant colonized in the genital tract by GBS to their baby during vaginal birth. While approximately 10 to 30% of pregnant people harbour GBS in the vagina or rectum, the incidence of neonatal GBS disease is 1 to 2 infants per 1000 births. The use of intrapartum antibiotics to treat colonized individuals with or without risk factors has led to a 70% decline in the incidence of early-onset GBS sepsis in the past decade. Despite this impressive decline, antibiotic resistance has become a major public health concern. Association between intrapartum antibiotic use and ampicillin resistance in E. coli isolated from neonates has previously been documented. Furthermore, while GBS has remained sensitive to penicillin, 20% are resistant to erythromycin and clindamycin, which are alternate drugs for patients allergic to penicillin. Alternative approaches are therefore needed to reduce the risk of GBS infection. We therefore propose to study the use of Lactobacillus rhamnosus GR-1 and Lactobacillus reuteri RC-14 (Lactobacillus fermentum RC-14) in the colonization status of GBS in pregnant people. Lactobacilli are part of normal gut and vaginal flora and have been widely used as probiotics to treat various conditions. In particular, these two strains have shown to be beneficial in the treatment of urinary tract infections and bacterial vaginosis. Our study design involves recruiting two hundred pregnant people (one hundred in each arm) through various midwifery practices in the GTA at the end of their first trimester of pregnancy. These individuals will be randomized to receive probiotics or placebo for twelve weeks of their pregnancies and will be cultured before delivery to determine their colonization status. The capsules with probiotics and placebo will be provided free of charge. The study design was chosen to minimize the cost and clients' visits to the clinic as vaginal/rectal swabs are routinely offered at 35-37 weeks of gestation.
NCT02528981 ↗	Effect of Probiotics on GBS Colonization Status During Pregnancy: A Pilot Randomized Controlled Trial	Completed	Chr Hansen A/S	N/A	2015-08-01	Group B Streptococcus (GBS) is the leading cause of neonatal morbidity and mortality in Canada. It may be passed from a study participant colonized in the genital tract by GBS to their baby during vaginal birth. While approximately 10 to 30% of pregnant people harbour GBS in the vagina or rectum, the incidence of neonatal GBS disease is 1 to 2 infants per 1000 births. The use of intrapartum antibiotics to treat colonized individuals with or without risk factors has led to a 70% decline in the incidence of early-onset GBS sepsis in the past decade. Despite this impressive decline, antibiotic resistance has become a major public health concern. Association between intrapartum antibiotic use and ampicillin resistance in E. coli isolated from neonates has previously been documented. Furthermore, while GBS has remained sensitive to penicillin, 20% are resistant to erythromycin and clindamycin, which are alternate drugs for patients allergic to penicillin. Alternative approaches are therefore needed to reduce the risk of GBS infection. We therefore propose to study the use of Lactobacillus rhamnosus GR-1 and Lactobacillus reuteri RC-14 (Lactobacillus fermentum RC-14) in the colonization status of GBS in pregnant people. Lactobacilli are part of normal gut and vaginal flora and have been widely used as probiotics to treat various conditions. In particular, these two strains have shown to be beneficial in the treatment of urinary tract infections and bacterial vaginosis. Our study design involves recruiting two hundred pregnant people (one hundred in each arm) through various midwifery practices in the GTA at the end of their first trimester of pregnancy. These individuals will be randomized to receive probiotics or placebo for twelve weeks of their pregnancies and will be cultured before delivery to determine their colonization status. The capsules with probiotics and placebo will be provided free of charge. The study design was chosen to minimize the cost and clients' visits to the clinic as vaginal/rectal swabs are routinely offered at 35-37 weeks of gestation.
NCT02528981 ↗	Effect of Probiotics on GBS Colonization Status During Pregnancy: A Pilot Randomized Controlled Trial	Completed	Ryerson University	N/A	2015-08-01	Group B Streptococcus (GBS) is the leading cause of neonatal morbidity and mortality in Canada. It may be passed from a study participant colonized in the genital tract by GBS to their baby during vaginal birth. While approximately 10 to 30% of pregnant people harbour GBS in the vagina or rectum, the incidence of neonatal GBS disease is 1 to 2 infants per 1000 births. The use of intrapartum antibiotics to treat colonized individuals with or without risk factors has led to a 70% decline in the incidence of early-onset GBS sepsis in the past decade. Despite this impressive decline, antibiotic resistance has become a major public health concern. Association between intrapartum antibiotic use and ampicillin resistance in E. coli isolated from neonates has previously been documented. Furthermore, while GBS has remained sensitive to penicillin, 20% are resistant to erythromycin and clindamycin, which are alternate drugs for patients allergic to penicillin. Alternative approaches are therefore needed to reduce the risk of GBS infection. We therefore propose to study the use of Lactobacillus rhamnosus GR-1 and Lactobacillus reuteri RC-14 (Lactobacillus fermentum RC-14) in the colonization status of GBS in pregnant people. Lactobacilli are part of normal gut and vaginal flora and have been widely used as probiotics to treat various conditions. In particular, these two strains have shown to be beneficial in the treatment of urinary tract infections and bacterial vaginosis. Our study design involves recruiting two hundred pregnant people (one hundred in each arm) through various midwifery practices in the GTA at the end of their first trimester of pregnancy. These individuals will be randomized to receive probiotics or placebo for twelve weeks of their pregnancies and will be cultured before delivery to determine their colonization status. The capsules with probiotics and placebo will be provided free of charge. The study design was chosen to minimize the cost and clients' visits to the clinic as vaginal/rectal swabs are routinely offered at 35-37 weeks of gestation.

Clinical Trial Conditions for erythromycin stearate

Condition Name

Condition Name for erythromycin stearate
Intervention	Trials
Group B Streptococcal Infection	1

Condition MeSH

Condition MeSH for erythromycin stearate
Intervention	Trials
Streptococcal Infections	1

Clinical Trial Locations for erythromycin stearate

Trials by Country

Trials by Country for erythromycin stearate
Location	Trials
Canada	1

Clinical Trial Progress for erythromycin stearate

Clinical Trial Phase

Clinical Trial Phase for erythromycin stearate
Clinical Trial Phase	Trials
N/A	1

Clinical Trial Status

Clinical Trial Status for erythromycin stearate
Clinical Trial Phase	Trials
Completed	1

Clinical Trial Sponsors for erythromycin stearate

Sponsor Name

Sponsor Name for erythromycin stearate
Sponsor	Trials
Chr Hansen	1
Chr Hansen A/S	1
Ryerson University	1

Sponsor Type

Sponsor Type for erythromycin stearate
Sponsor	Trials
Industry	2
Other	1

Erythromycin stearate Market Analysis and Financial Projection

Last updated: April 25, 2026

Clinical Trials, Market Analysis, and Projections for Erythromycin Stearate

What is erythromycin stearate and where is it used clinically?

Erythromycin stearate is a salt form of the macrolide antibiotic erythromycin, used to improve oral handling characteristics compared with erythromycin base. In clinical practice, erythromycin class positioning remains the same: treatment of bacterial infections where susceptible organisms are present and where macrolide therapy is appropriate. Regulatory and marketing status is largely tied to the approved erythromycin stearate oral products in each market and to the underlying therapeutic labeling of erythromycin (infection categories vary by jurisdiction and product).

From a patent and R&D standpoint, erythromycin stearate generally tracks older-generation antibiotic frameworks rather than a new chemical entity; commercial value typically depends on formulation, bioavailability, compliance, and supply continuity rather than novel mechanism claims.

What clinical trial activity exists for erythromycin stearate?

No complete and auditable clinical-trials dataset for “erythromycin stearate” as a distinct investigational drug across registries and timeframes is available in the information provided here. A reliable update requires trial-level identifiers (NCT/EudraCT), enrollment status, endpoints, and sponsor at minimum. Under a strict evidence standard, this cannot be produced without traceable trial records.

How does the market look for erythromycin products, and what does stearate imply?

Erythromycin is an established, older antibiotic class with mature competitive dynamics dominated by:

• Generic oral macrolides and generic erythromycin formulations
• Institutional purchasing patterns that favor low-cost, stable supply, and proven formulations
• Shifting utilization patterns due to newer macrolides and antimicrobial stewardship policies

Erythromycin stearate is typically a formulation/brand variant rather than a standalone “platform” generating incremental demand like a new active. That means market sizing and projections usually map to: 1) the share of erythromycin oral prescriptions within the relevant indication set, and
2) the share of those prescriptions that use stearate-form oral products versus alternatives (other erythromycin salts, estolate/ethylsuccinate where available, or other macrolides).

How big is the opportunity and what drives near-term demand?

Without a registry-quality clinical evidence base and without segmentable, product-level sales history in the inputs provided here, the only defensible market view is structural:

Demand drivers

• Low-cost generic access for established infections where macrolides remain appropriate
• Continued availability of pediatric and specialty oral formulations in certain geographies
• Local guideline alignment and formulary inclusion for erythromycin-class therapy

Erosion drivers

• Competition from newer macrolides and alternative antibiotic classes
• Stewardship pressure and guideline shifts away from older macrolides in some settings
• Margin compression from multi-source generics and price competition

Commercial implication for erythromycin stearate Erythromycin stearate’s commercial trajectory will likely follow overall erythromycin oral erosion patterns: stable-to-declining volumes in mature markets, with sporadic growth only where specific formulations are preferred or where supply gaps occur.

How should investors and R&D teams project revenue without a trial pipeline?

For mature antibiotics without a distinct, active investigational pipeline, a projection model usually relies on:

• Formulary and tender outcomes (contracts)
• Switch-and-continue patterns among prescribers and pharmacists
• Regulatory maintenance and product availability (manufacturing continuity)
• Generic pricing indices and channel inventory cycles

A defensible projection requires historical revenue or unit data and contract history for erythromycin stearate, which is not present in the input. Under strict auditability, a numeric revenue forecast cannot be produced.

What are the likely regulatory and patent considerations that affect supply and pricing?

Erythromycin stearate is not typically protected by broad composition-of-matter in modern commercial terms; protection often centers on:

• Formulation-specific claims (salt form, particle characteristics, manufacturing process)
• Method-of-use claims tied to specific dosing regimens or patient subgroups
• Packaging, stability, and process improvements

For a business planning horizon, the key operational risk is supply and regulatory status continuity rather than patent-driven exclusivity. Commercial risk usually clusters around:

• Manufacturing capability and scale-up
• Quality system adherence and pharmacopoeial compliance
• Shelf-life stability and bioequivalence constraints

Is there any “clinical trial update” that changes market expectations for erythromycin stearate?

No such update can be substantiated here without traceable trial registries and trial status details for erythromycin stearate specifically.

---

Market Outlook Framework (Non-numeric, decision-useful)

How should you assess near-term market stability?

Use a three-factor screen: 1) Channel availability: number of suppliers and manufacturing disruptions risk
2) Price elasticity: tender-driven price declines in the last two to three procurement cycles
3) Therapeutic demand stability: guideline and stewardship changes impacting macrolide use in the relevant indication set

For erythromycin stearate, this screen generally points to: stable availability risk as the primary variable, with pricing pressure from generic competition as the baseline.

What business scenarios are most likely?

• Base case: stable volume, declining or flat pricing (typical mature generic behavior)
• Downside case: accelerated erosion from substitution toward other macrolides and other antibiotic classes
• Upside case: temporary share gains from local formulary preferences or supply constraints affecting alternative products

Where does R&D still create value for erythromycin stearate?

Value creation usually comes from:

• Improved oral formulation performance (bioavailability consistency across lots)
• Pediatric-friendly dosing accuracy and palatability (where product design matters)
• Stability and shelf-life extension to reduce wastage and expand tender eligibility

This is not evidence that new clinical trial breakthroughs exist; it is a statement about how formulation work reduces execution friction for mature antibiotics.

---

Key Takeaways

• Erythromycin stearate is a mature, formulation-linked macrolide salt; commercial performance typically tracks erythromycin oral demand and generic pricing dynamics rather than new mechanism adoption.
• A clinical trials update cannot be produced here to a strict evidence standard because trial identifiers and status records for “erythromycin stearate” are not available in the provided inputs.
• Market projections for erythromycin stearate require product-level sales, tender history, and supplier/regulatory continuity data, which are not present; a numeric forecast is not supportable.
• Decision-grade strategy should focus on supply continuity, formulary/tender positioning, and formulation execution rather than assuming a near-term clinical pipeline catalyst.

---

FAQs

1. Is erythromycin stearate considered a new drug candidate?
   No. It is a mature erythromycin salt form tied to existing macrolide therapeutic use.

2. What drives earnings for erythromycin stearate suppliers?
   Tender-driven pricing, reliable manufacturing supply, and formulation acceptance (including stability and bioequivalence performance).

3. Can clinical trial activity materially shift the erythromycin stearate market?
   Only if there is registry-verified, indication-relevant trial readout that changes labeling or guideline positioning. No such substantiated activity is provided here.

4. How should you benchmark competitive pressure?
   Use generic macrolide pricing, number of active suppliers in the target geography, and formulary substitution patterns toward other oral macrolides or alternative antibiotics.

5. What R&D areas still matter for a mature antibiotic salt?
   Formulation improvements that reduce variability, improve dosing experience, and extend shelf-life to maintain tender eligibility.

---

References

[1] U.S. National Library of Medicine. ClinicalTrials.gov. https://clinicaltrials.gov/
[2] European Medicines Agency. European Union Clinical Trials Register. https://www.clinicaltrialsregister.eu/
[3] U.S. FDA. Drugs@FDA. https://www.accessdata.fda.gov/scripts/cder/daf/